Research programme: Bruton's tyrosine kinase inhibitors - Pharmacyclics
Alternative Names: PCI-45261; PCI-45292Latest Information Update: 04 Nov 2017
At a glance
- Originator Pharmacyclics
- Class Small molecules
- Mechanism of Action Agammaglobulinaemia tyrosine kinase inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- No development reported Autoimmune disorders; Hypersensitivity; Rheumatoid arthritis
Most Recent Events
- 04 Nov 2017 No recent reports of development identified for preclinical development in Allergy in USA (PO)
- 04 Nov 2017 No recent reports of development identified for preclinical development in Autoimmune-disorders in USA (PO)
- 04 Nov 2017 No recent reports of development identified for preclinical development in Rheumatoid-arthritis in USA (PO)